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Introduction
Aplastic anemia is a form of anemia in which the bone marrow 
fails to produce adequate numbers of peripheral blood elements. 
The incidences of atherosclerosis and myocardial infarction in pa-
tients with congenital coagulation disorders and chronic thrombo-
cytopenia are very low. However in cases requiring invasive proce-
dures (e.g., dental procedure and endoscopic procedure), patients 
at times need platelet transfusion. In this paper, a case of late stent 
thrombosis was reported within 4 hours after transfusion of plate-
lets for anticipated bleeding in an aplastic anemia patient.
Case
A 52-year-old man who had been diagnosed with aplastic anemia 
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and stable angina visited the emergency room of the authors’ hos-
pital with a complaint of chest pain. The chest pain had developed 
1 hour before the patient’s arrival at the hospital. The initial electro-
cardiogram showed a hyperacute tall T wave in the precordial leads 
(Fig. 1). In the initial laboratory findings, the cardiac markers were in 
the normal range, but thrombocytopenia was noted (initial white 
blood cell count: 3350, hemoglobin: 12.5 g/dL, platelet: 45000/μL). 
The patient’s vital signs were stable. His past history revealed that 
he had been admitted to a hospital a year ago for acute coronary syn-
drome and percutaneous coronary intervention (PCI) of the left an-
terior descending artery (LAD), for which a Cypher Select stent (3.5× 
28 mm, Johnson & Johnson-Cordis, Miami, FL, USA) procedure was 
performed (Fig. 2). He had been taking 100 mg of aspirin, 75 mg of 
clopidogrel and 100 mg of oxymetholone (anabolic steroids) for ap-
lastic anemia daily since the last one year. However, he had stopped 
taking aspirin and clopidogrel for 3 days before presenting himself 
at the hospital since he was scheduled to be treated for a decayed 
tooth. He also visited the hematology clinic routinely. His laboratory 
findings showed that he had severe thrombocytopenia (platelet 
count: 12000/μL). His hematologist recommended platelet trans-
fusion for anticipated bleeding. Therefore, transfusion of 6 pints of 
platelet concentrates was performed on the same day of the pati-
ent’s visit to the hospital. Four hours later, he developed chest pain. 
The emergent coronary angiography demonstrated total occlu-
sion of the mid-LAD. Balloon angioplasty was done with a 3.0×15 
mm non-complaint coronary balloon. Thrombolysis in myocardial 
infarction 3 distal flow was obtained. Thus, no additional stent was 55 Hyun-Sung Shin, et al.
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needed (Fig. 3). 
A dose of 7,000 units of unfractionated heparin was injected 
during the CAG with another loading dose of 300 mg of clopidogrel. 
After the PCI, the chest pain subsided. On the second day, blood 
started oozing from the puncture site, hence a manual compression 
dressing was applied for 1 hour, after which there was no more com-
plications. The follow-up platelet count was 12000/μL. On the 12th 
day, the patient’s dental caries was treated with tooth extraction 
without bleeding complications, and the patient was discharged. 
He was prescribed triple antiplatelet therapy with aspirin, clopido-
grel, and cilostazol. He was also asked to continue oxymetholone 
(anabolic steroids) therapy for aplastic anemia. 
Discussion
 
Aplastic anemia is a form of anemia in which the bone marrow 
fails to produce adequate numbers of peripheral blood elements. The 
incidences of atherosclerosis and myocardial infarction in patients 
with congenital coagulation disorders and chronic thrombocyto-
penia are very low.
There are a few reports of cases of aplastic anemia associated 
with myocardial infarction during treatment with anabolic steroids.
1) 
Steroids have been commonly used to treat aplastic anemia, are a 
possible risk factor for coronary thrombosis, because steroids have 
an accelerating effect on metabolic changes and can induce a hy-
percoagulable state, each of which may promote atherosclerosis. 
Therefore, steroids may have helped to precipitate the clinical events 
in the patient.
2) Andrade et al.
3) reported a case of acute stent throm-
bosis in a patient with giant cell arteritis, but there is no case report 
of long-term oral steroid therapy associated with very late stent th-
rombosis.
Even if other risk factors for stent thrombosis (e.g., incomplete 
Fig. 1. Initial electrocardiogram showed hyperacute tall T wave in the precordial leads.
Fig. 2. One year before this event, coronary angiography revealed a diffuse, eccentric luminal narrowing up to 90% (A) and percutaneous coronary inter-
vention with Cypher Select 3.5×28 (Johnson & Johnson-Cordis, Miami, FL, USA) was performed due to acute coronary syndrome (arrows) (B).
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Fig. 3. Coronary angiography of the left coronary artery. Total occlusion of the mid left anterior descending artery in the portion of the previously inserted 
stent (A) was noted (arrows). After balloon angioplasty with 3.0×15 mm non-complaint coronary balloon, thrombolysis in myocardial infarction 3 distal 
flow was obtained (B).
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